EE260 Cost-Effectiveness Analysis of Sacituzumab Govitecan As Second-Line Treatment for Metastatic Triple-Negative Breast Cancer in Japan

Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.561
https://www.valueinhealthjournal.com/article/S1098-3015(23)00661-7/fulltext
Title : EE260 Cost-Effectiveness Analysis of Sacituzumab Govitecan As Second-Line Treatment for Metastatic Triple-Negative Breast Cancer in Japan
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00661-7&doi=10.1016/j.jval.2023.03.561
First page :
Section Title :
Open access? : No
Section Order : 10043
Categories :
Tags :
Regions :
ViH Article Tags :